SELLAS Life Sciences (SLS) Stock Surges Over 200% After Phase 3 Leukemia Vaccine Win

In this news:

Key takeaways

  • SELLAS Life Sciences stock jumped more than 200% after positive Phase 3 REGAL results for its leukemia vaccine GPS.
  • GPS cut the risk of death by 41%; median survival was 24.0 months versus 14.7 months.
  • SELLAS plans to meet the FDA and file for approval in the first half of 2027.

SELLAS Life Sciences (SLS) stock jumped more than 200% on Tuesday. The move came after the company reported positive Phase 3 results for its leukemia vaccine.

One early report put the gain at 240% at its peak. Buyers clearly wasted no time.

What the REGAL Trial Showed

The trial tested galinpepimut-S, known as GPS, in acute myeloid leukemia (AML). It met its main goal of overall survival.

Patients on GPS had a 41% lower risk of death than those on the best available treatment. The hazard ratio was 0.59, and the two-sided p-value was 0.035.

Median survival reached 24.0 months with GPS. The control group reached 14.7 months.

The analysis ran after 80 events, as the trial plan required. That timing was set in advance.

Everyone in the study had reached a second or later complete remission. They also could not have a stem cell transplant, or were not eligible for one.

GPS was given alone as maintenance therapy. Its safety profile matched earlier experience, with no new safety signals.

Most side effects were mild to moderate. The most common were reactions at the injection site.

What Comes Next for SELLAS

SELLAS plans to meet with the FDA to discuss a faster filing path. It is also preparing a Biologics License Application for the first half of 2027.

More detailed trial data is expected at an upcoming medical conference. The company has not been tied to a date in the reports.

A second leukemia drug is also moving along. Tambiciclib, or SLS009, is a CDK9 inhibitor in Phase 2 testing.

Forty patients have enrolled in its study of newly diagnosed AML. Early findings are expected before year-end.

More SLS009 data is headed to the American Society of Hematology meeting in December. Earlier work in relapsed or resistant AML showed response rates of 54% in monocytic AML and 57% in patients with TP53 mutations.

SELLAS ended September with $134.7 million in cash and equivalents. Its third-quarter net loss was $10.1 million, up from $6.8 million a year earlier.

Maxim analyst Jason McCarthy rates the stock a Buy with a $30 price target. He models GPS revenue starting in 2027 and SLS009 in first-line AML in 2029.

Tuesday’s rally has pushed the stock much closer to that target.

Source: blockonomi.com

Share the article:

Top Trending Cryptocurrencies on The Market

Current Price

$99.760

7 Days
GNO 7 days: -8.05%

Market Cap

$263.3M 3.09%

24h Volume

$581.4K

Supplies

3.0M / 3.0M

Current Price

$0.03847

7 Days
SEI 7 days: -9.44%

Market Cap

$259.0M -1.98%

24h Volume

$21.7M

Supplies

10.0B / ∞

Current Price

$1.028

7 Days
SAFO 7 days: +0.08%

Market Cap

$256.1M 0.51%

24h Volume

-

Supplies

249.1M / ∞

Current Price

$0.03231

7 Days
STRK 7 days: -7.84%

Market Cap

$253.2M -0.71%

24h Volume

$44.5M

Supplies

10.2B / ∞

Current Price

$1.440

7 Days
PENDLE 7 days: -4.15%

Market Cap

$250.2M 2.35%

24h Volume

$39.1M

Supplies

281.5M / ∞

Current Price

$0.9999

7 Days
RUSD 7 days: +0%

Market Cap

$249.9M -0.07%

24h Volume

$131.6M

Supplies

5.0B / ∞

Current Price

$0.00004505

7 Days
LUNC 7 days: +23.81%

Market Cap

$248.8M 15.06%

24h Volume

$40.3M

Supplies

6.4T / ∞

Current Price

$0.9419

7 Days
BP 7 days: +9.69%

Market Cap

$235.5M -6.64%

24h Volume

$3.9M

Supplies

1000.0M / 1.0B

Current Price

$15.510

7 Days
OHM 7 days: +0.99%

Market Cap

$231.2M -0.14%

24h Volume

$208.9K

Supplies

19.8M / ∞

Current Price

$0.2091

7 Days
XTZ 7 days: -10.1%

Market Cap

$230.4M 0.11%

24h Volume

$4.4M

Supplies

1.1B / ∞

Current Price

$1.000

7 Days
PC0000031 7 days: +0%

Market Cap

$227.5M 0%

24h Volume

-

Supplies

227.5M / 400.0M

Current Price

$0.04761

7 Days
XPL 7 days: -4.13%

Market Cap

$226.7M 2.43%

24h Volume

$28.8M

Supplies

10.0B / ∞

Notifications Login to see

Today

No Notifications

↑